← Back to Screener
Akari Therapeutics plc ADR (0.01 USD) (AKTX)
Price$5.94
Favorite Metrics
Price vs S&P 500 (26W)-93.16%
Price vs S&P 500 (4W)2.05%
Market Capitalization$6.56M
All Metrics
Book Value / Share (Quarterly)$0.00
P/TBV (Annual)15.76x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)-53.97%
EPS (TTM)$-0.01
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-0.01
EPS (Annual)$-0.00
ROI (Annual)-59.48%
Cash / Share (Quarterly)$0.00
ROA (Last FY)-36.12%
EBITD / Share (TTM)$-0.00
ROE (5Y Avg)-327.53%
Cash Flow / Share (Annual)$-0.00
P/B Ratio0.23x
P/B Ratio (Quarterly)0.31x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-10.29x
ROA (TTM)-35.46%
EPS Incl Extra (Annual)$-0.00
Current Ratio (Annual)0.44x
Quick Ratio (Quarterly)0.43x
3-Month Avg Trading Volume0.02M
52-Week Price Return-86.82%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.00
52-Week High$63.20
EPS Excl Extra (Annual)$-0.00
Tangible BV CAGR (5Y)-44.65%
26-Week Price Return-84.41%
Quick Ratio (Annual)0.43x
13-Week Price Return-45.90%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)0.44x
Enterprise Value$2.115
Book Value / Share Growth (5Y)-55.29%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.00
3-Month Return Std Dev107.80%
Net Income / Employee (TTM)$-2
ROE (Last FY)-61.06%
Net Interest Coverage (Annual)-10.29x
EPS Basic Excl Extra (Annual)$-0.00
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-0.01
Receivables Turnover (Annual)0.00x
ROI (TTM)-66.13%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.00
Price vs S&P 500 (52W)-121.91%
Year-to-Date Return-49.83%
5-Day Price Return36.55%
EPS Normalized (Annual)$-0.00
ROA (5Y Avg)-116.59%
Month-to-Date Return12.62%
Cash Flow / Share (TTM)$-15.64
EBITD / Share (Annual)$-0.00
ROI (5Y Avg)-324.94%
EPS Basic Excl Extra (TTM)$-0.01
P/TBV (Quarterly)6.22x
P/B Ratio (Annual)0.31x
Book Value / Share (Annual)$0.00
Price vs S&P 500 (13W)-48.76%
Beta0.69x
Revenue / Share (TTM)$0.00
ROE (TTM)-70.34%
52-Week Low$3.25
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AKTXAkari Therapeutics plc ADR (0.01 USD) | — | — | — | — | $5.94 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Akari Therapeutics develops next-generation antibody-drug conjugates (ADCs) utilizing proprietary cancer-targeting payloads designed to improve upon existing therapies. The company's lead candidate, AKTX-101, is a preclinical Trop2-targeting ADC addressing solid tumors including lung, breast, colon, and prostate cancers. Akari's novel payload approach aims to enhance both the efficacy and safety profiles of current ADC treatments.